Millendo Therapeutics Inc (MLND) Stock Price, Forecast & Analysis
NASDAQ:MLND
MLND Key Statistics, Chart & Performance
The current stock price of MLND is 1.06 null. In the past month the price decreased by -7.02%. In the past year, price decreased by -41.44%.
MLND Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MLND. When comparing the yearly performance of all stocks, MLND is a bad performer in the overall market: 98.82% of all stocks are doing better.
MLND Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MLND. MLND has a bad profitability rating. Also its financial health evaluation is rather negative.
MLND Financial Highlights
Over the last trailing twelve months MLND reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS increased by 44.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.44% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
MLND Forecast & Estimates
0 analysts have analysed MLND and the average price target is 2.04 null. This implies a price increase of 92.45% is expected in the next year compared to the current price of 1.06.
MLND Ownership
MLND Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 409.148B | ||
| AMGN | AMGEN INC | 16.38 | 198.801B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 192.281B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 124.696B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 84.911B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 41.535B | ||
| INSM | INSMED INC | N/A | 31.724B | ||
| BIIB | BIOGEN INC | 12.92 | 28.841B | ||
| NTRA | NATERA INC | N/A | 28.695B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.396B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MLND
Company Profile
Millendo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Ann Arbor, Michigan. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The firm's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Company Info
Millendo Therapeutics Inc
Ann Arbor MICHIGAN 48104 US
CEO: Louis Arcudi
Phone: 17348459000.0
Millendo Therapeutics Inc / MLND FAQ
What does Millendo Therapeutics Inc do?
Millendo Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Ann Arbor, Michigan. The company went IPO on 2012-10-04. Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs are TPST-1495 and TPST-1120. The firm's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
What is the current price of MLND stock?
The current stock price of MLND is 1.06 null. The price decreased by -5.36% in the last trading session.
Does Millendo Therapeutics Inc pay dividends?
MLND does not pay a dividend.
What is the ChartMill rating of Millendo Therapeutics Inc stock?
MLND has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.